Navigation Links
Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance
Date:2/12/2008

Company Reiterates 2008 Earnings Guidance and Introduces Q1 2008 Guidance

FRAZER, Pa., Feb. 12 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported 2007 sales of $1.727 billion, compared to sales of $1.720 billion for 2006, exceeding the company's previously issued guidance. Basic loss per common share for the full year 2007 was $2.88. Excluding the previously announced settlement reserve, amortization expense and certain other items, basic adjusted income per common share for the full year was $4.64, which compares to $5.22 for 2006 and exceeds the high end of the company's earnings guidance range of $4.45 to $4.55.

2007 central nervous system (CNS) franchise sales increased 16 percent to $909.4 million compared to 2006 and the pain franchise reported strong sales of $512.6 million, a decrease of only 22 percent despite a full year of generic competition to ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. Sales of other products increased 15 percent to $305.3 million.

"We delivered strong performance across all aspects of our business in 2007. We launched AMRIX, filed three NDAs, introduced three new Phase 1 programs, and delivered greater sales and earnings than expected," said Frank Baldino, Jr., Ph.D., Chairman and CEO. "We believe that 2008 will mark the beginning of a new phase of growth for the company with a full year of AMRIX sales, the potential for approval of TREANDA and expanded indications for FENTORA, and continued progress on the clinical development plan for NUVIGIL. In fact, the NUVIGIL program is already off to a great start with promising results from our first Phase 2 study in the treatment of schizophrenia."

The company is reiterating its guidance for 2008 total sales of $1.80 - $1.85 billion, adjusted net income of $344 - $351 million and its basic adjusted income per common share guidance of $5.10 - $5.20.

Cephalon is introducing first quarter 2008 sales guidance of $435 - $445 mil
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. CNS Response Announces Fiscal Third Quarter 2007 Results
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Martek to Announce Third Quarter 2007 Results on September 5, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 Date: Friday, April 11, 2014 ... Country Club, 1360 Almshouse Road, Warrington, Pa. , ... solely dedicated to finding a cure for hepatitis B and ... host its annual Crystal Ball on Friday, April 11 at ...
(Date:1/14/2014)... , Jan. 14, 2014 As pet owners drew up their ... of them wrote: "Take better care of my furry companion." Nowadays ... clothes and top-brand carrying cases to take the little canine or ... also feel compelled to buy some pricey toys at the pet ...
(Date:1/14/2014)... 2014 iLab Solutions, the leader in core ... Director of Product Strategy. In this role, Michelle will work ... to guide in the development of iLab products. Her main ... possible benefit to the scientific community by offering the most ...
(Date:1/14/2014)...   Kinaxis ®, provider of RapidResponse ®, a cloud-based ... planning ( S&OP ) service, is proud to be a ... be held at the Hilton San Diego Bayfront, January 30 ... Elisabeth Kaszas , Director of Supply Chain at Amgen, as ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... , SAN DIEGO, July 27 Neurocrine Biosciences (Nasdaq: NBIX ) ... Neurocrine Biosciences Webcast, When: July 30, 2009 ... Live over the Internet -- Simply log on to the web ... above., Contact: Jane Sorenson of Neurocrine Biosciences, +1-858-617-7653., , ...
... , , , ... (PTC) today announced the initiation of a Phase 2 clinical ... (NF2), a rare genetic disorder that causes the development of ... investigational new drug that is designed to selectively block tumor-related ...
... Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY ) announced ... SAFC Pharma(R), a Division of Sigma-Aldrich Corporation, it has ... under cGMP conditions. This run is anticipated to be ... the next several years as Oncolytics provides product for ...
Cached Biology Technology:PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2 2PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2 3PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2 4Oncolytics Biotech Inc. Successfully Completes 100-Litre cGMP Production of REOLYSIN(R) 2
(Date:7/9/2014)... are turning to more healthful alternatives to their savored ... mean low satisfaction. Now researchers are reporting new progress ... are made with olive oil rather than pork fat. ... Agricultural and Food Chemistry . , Ana M. Herrero ... expect just the right amount of chewiness and springiness, ...
(Date:7/9/2014)... on the verge of an economy driven by methane, the ... and is undergoing a production boom. It has poised the ... is casting serious doubts over just how climate-friendly it is, ... (C&EN), the weekly news magazine of the American Chemical ... at C&EN, explains that when burned as a fuel to ...
(Date:7/9/2014)... protect neuronal function and increase the survival rate ... her team, School of Pharmaceutical Sciences, Southwest University, ... mice were administered with low dose of levothyroxine ... aged rats exhibited an obvious improvement in cognitive ... to 93%. The underlying mechanism was demonstrated that ...
Breaking Biology News(10 mins):
... The first State of the Carbon Cycle Report for North ... Science Program, finds the continents carbon budget increasingly overwhelmed by ... tons of carbon into the atmosphere each year, mostly as ... may remove up to half this amount, but these current ...
... In the December 1st issue of G&D, Dr. Hailing ... of a new class of small RNAs in Arabidopsis. ... dubbed long short interfering RNAs (lsiRNAs), and are induced ... liRNAs share some hallmark features with other, previously identified ...
... Researchers from Kaiser Permanente and the California Department of ... nationwide, today will begin enrolling families in the largest ... that may cause autism and other developmental disabilities. ... Early Development, will involve 2,700 children and their parents ...
Cached Biology News:First-ever 'State of the Carbon Cycle Report' finds troubling imbalance 2Largest study to investigate risk factors of autism to begin enrolling families 2
WD-repeat protein 4...
Rabbit polyclonal to MDM2 (phospho S185) ( Abpromise for all tested applications). entrezGeneID: 4193 SwissProtID: Q00987...
... human omental preadipocytes are ... otherwise healthy donors. There ... diabetic cells. Please inquire ... media also available. Academic ...
ASCIZ...
Biology Products: